Introduction Here, we summarize a retrospective comparison of EasyM and Euroflow NGF for MRD in newly diagnosed multiple myeloma patients. Minimal residual disease (MRD) negativity is a critical measure of therapeutic response in multiple myeloma (MM) and is strongly associated with improved progression-free and overall survival. The IMWG (International Myeloma Working Group) [...]
Introduction Minimal residual disease (MRD) has emerged as a critical prognostic marker in multiple myeloma (MM). Traditional MRD assessment relies heavily on bone marrow–based methods such as multiparameter flow cytometry (MFC), next-generation flow cytometry (NGF), and next-generation sequencing (NGS). However, these are invasive, costly, and limited in their ability to capture disease [...]
Mariya Liyasova, Zac McDonald, Paul Taylor, Kathleen Gorospe, Xin Xu, Chenyu Yao, Qixin Liu, Liqiang Yang, Eshetu G Atenafu, Giovanni Piza, Bin Ma, Donna Reece, Suzanne Trudel DOI: 10.1158/1078-0432.CCR-21-0649 Publication Summary M-protein is a well-established biomarker used for multiple myeloma monitoring. Current improvements in multiple myeloma treatment created the need to monitor minimal residual disease (MRD) with high sensitivity. Measuring residual levels of [...]
Zac McDonald, Paul Taylor, Mariya Liyasova, Qixin Liu, Bin Ma DOI: 10.1021/acs.jproteome.0c01022 Publication Summary The amino acid sequence of the M-protein for multiple myeloma is unique compared to the polyclonal antibodies in patients’ blood. This uniqueness is exploited to develop an ultrasensitive M-protein detection method utilizing mass spectrometry (MS). This study demonstrates [...]